Early Trial Results for Experimental Pancreatic Cancer Pill ERAS-0015 Prompt Optimism from Canadian Oncologists

pancreatic cancer drug trial: An experimental pill from San Diego-based Erasca shrank tumours in 44 per cent of 25 patients with advanced pancreatic cancer in early testing, according to the company. Canadian oncologists describe the results as a major step, though the trial was small and the drug remains unapproved.

Pancreatic cancer drug trial, Digimart Global: An experimental U.S. drug has shown positive early results in patients with advanced cancer, and Canadian doctors are calling it a significant breakthrough.

Erasca, a drugmaker based in San Diego, Calif., reported on Friday that its pill, ERAS-0015, reduced tumours in nearly half of the patients in an early-stage clinical trial.

According to Erasca, 44 per cent of 25 patients with pancreatic cancer saw their tumours shrink substantially after taking a 32 mg daily dose. The company also said 69 per cent of patients with the two most common genetic variations of pancreatic cancer had positive results.

In lung cancer, tumours diminished in three of five patients (60 per cent) who had previously received immunotherapy and chemotherapy.

Dr. Jennifer Knox, a staff medical oncologist at the University Health Network’s Princess Margaret Cancer Centre in Toronto, called the results “the biggest breakthrough for pancreas cancer probably ever” in a phone interview with CTV News.

She said the trial’s small size is typical for this phase, and she expects a large number of Canadian participants when the global late-stage trial reaches Canada next year.

A broader push against the RAS protein

Knox said a separate experimental drug, daraxonrasib, also targeting the mutant RAS protein, doubled survival time in a clinical trial, according to a U.S.-led study published in The New England Journal of Medicine in May. That drug was developed by Revolution Medicines.

Knox said ERAS-0015 is similar and that daraxonrasib is now licensed in the U.S.

RAS proteins act as on-off switches for cell growth and can drive cancer when they mutate. Erasca said the pill was generally well tolerated, although it had previously reported that one patient taking a 24 mg dose died from lung inflammation.

Caution from researchers

Dr. Sam Godfrey of Cancer Research UK said he was optimistic, noting that patients receiving treatment for pancreatic cancer normally have less than a year to live.

He cautioned that longer trials are needed, because microscopic cancer cells can remain and return. Erasca said it will begin late-stage trials of ERAS-0015 and another experimental treatment, ERAS-4001, in 2027.

Leave a Reply

Your email address will not be published. Required fields are marked *

Sports

Explore Digimart Global